Navigation Links
ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies
Date:6/23/2011

DALLAS, June 23, 2011 /PRNewswire/ --


- ReportsnReports announces it will carry 'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies'Report in its store

Browse the complete ' Multitargeted Therapies: Promiscuous Drugs and Combination Therapies'Report now!

Search 75000+ Market Research Reports

Browse All Pharmaceuticals Market Research Reports

Report Summary

Suites of drugs have been developed that can be used in combination to treat complex diseases that have multiple causes involving multiple targets. In addition, it has been found that many successful small-molecule drugs are promiscuous, i.e., they are single drugs that address multiple targets. This report on Multitargeted Therapies covers both these major approaches to development of multitargeted therapies. Discussed are:

  • The discovery and design of promiscuous drugs
  • The rational design of novel combination therapies designed to address multiple targets, including the uses of synthetic lethality and pathway biology
  • The emerging area of network pharmacology
  • Chemical proteomics methods designed to assess the degree of promiscuity of kinase inhibitors and to develop specifically multitargeted kinase inhibitors
  • The development of second-generation agents to overcome resistance to therapy

Modern drug discovery is generally based on a reductionist model, in which a molecular target has a causative role in a disease process, and modulating that target should ameliorate or cure the disease. This paradigm has resulted in the successful development of numerous therapeutic agents. However, over the past decade, several major factors have been identified that result in the high rates of clinical attrition seen today. One of the biggest factors is that researchers have been addressing complex diseases that are caused by multiple genetic and environmental factors. Thus the reductionist model may not hold in these cases, and drug therapies that address multiple targets are needed.

'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies' discusses the emerging discipline of network pharmacology, which combines network biology with chemogenomics. Network pharmacology demonstrates that most approved small-molecule drugs are promiscuous. It can be used to develop computational tools to predict the biological activity of compounds, to find new targets for approved drugs as well as for drugs that failed in clinical trials due to efficacy but not safety, and to design new multitargeted drugs.

Also discussed are multitargeted kinase inhibitors. Most kinase inhibitors are promiscuous, and often the efficacy of a kinase inhibitor against a particular type of cancer depends on its ability to address multiple targets. Moreover, the multitargeted nature of a kinase inhibitor may enable its use in treating more than one type of cancer. However, kinase inhibitors may also exhibit off-target adverse effects. We present chemical proteomics methods designed to assess the degree of promiscuity of kinase inhibitors and to develop specifically multitargeted kinase inhibitors.

'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies' also focuses on development of novel combination therapies designed to address multiple targets. Discussed is the use of synthetic lethality to design combination therapies for cancer. We describe the use of synthetic lethal screening with RNAi to identify chemosensitizing targets for cancer therapeutics. Also described is an RNAi-based synthetic lethal screening approach to developing therapies for p53-negative cancers (p53 is a key tumor suppressor factor in the majority of human cancers).

Another area of focus covered in this report is the use of pathway biology to design rational combination therapies for cancer. Three case studies are included, which involved studying intracellular signaling pathways and how they are affected in cancers that are resistant to certain drugs. These studies were then used to design patient-specific combination therapies to overcome this resistance.

Related & Latest Reports:


About Us

ReportsnReports comprises an online market research library of 75,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Follow Us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
http://www.reportsnreports.com/
Blog: http://www.reportsnreportsblog.com/



'/>"/>
SOURCE ReportsnReports
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
5. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
6. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
7. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
8. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
(Date:2/16/2017)... -- Prescription pain medications provided by "physicians in the months ... opioid use to take hold," according to a new ... The New England Journal of Medicine (NEJM). ... acute pain than in almost any other medical setting," ... the American College of Emergency Physicians. "The challenge is ...
(Date:2/16/2017)... Research and Markets has announced the addition of the "Global ... Cancer Type, Technology - Forecast to 2025" report to their ... The ... a CAGR of around 28.6% over the next decade to reach ... the prominent trends that the market is witnessing include increasing demand ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today announced that ... Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will be the ... patient signatures solution in healthcare . , Since it first introduced Electronic ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow ... Tri-Conference February 20 – 22 in San Francisco. As part of the Tri-Conference ... molecular pathology workflow solution, as well as its new precision medicine platform, “Crosswalk ...
(Date:2/16/2017)... New York, New York (PRWEB) , ... February ... ... hard work and determination. After what took over 10 years of research, development ... disruptive technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ...
Breaking Medicine News(10 mins):